625% rally in five years! Multibagger stock Kellton Tech Solutions share price edges higher despite stock market crash.
Stock Market Today: Having risen 625% rally in five years, the Multibagger stock Kellton Tech Solutions share price gained higher on Tuesday despite stock market crash. Here's why
Kellton Tech Solutions intimated the National Stock Exchange of India and the BSE Ltd on Tuesday 13 , May 2025 about the outcome of the Board meeting. The Board of Directors of Kellton Tech Solutions gave Approval of $ 10,000,000 of 6.50% Senior Unsecured foreign currency convertible bonds due 2035 of Kellton Tech Solutions Limited ("FCCBs")
Kellton Tech Solutions had intimation on May 08, 2025, about having obtained the approval of the members of the Company through Postal Ballot conducted between December 23, 2024 and January 22, 2025, for the proposed issuance of foreign currency convertible bonds (FCCBs).
Kellton Tech Solutions said based on the In-principle approvals granted by BSE Limited and National Stock Exchange of India Limited on February 20, 2025, the Board of Directors of the Company, at its meeting held on May 13, 2025, has, considered and approved the matters in connection with the aforesaid offering,
While the Board approved the Issuance of $ 10,000,000 6.50% senior unsecured foreign currency convertible bonds due 2035 of Kellton Tech Solutions Limited ("FCCBs"), it also approved the 'Relevant Date' for the purpose of the Issue of FCCBs as May 13, 2025 in accordance with the Issue of Foreign Currency Convertible Bonds and Ordinary Shares
Regulatory Floor Price Also the regulatory floor price as determined in accordance with the FCCBs Guidelines is Rs.107.00, the Final identification of investors and other associated matters shall be subject to the outcome of the open offer process, and the same shall be intimated in due course , said Kellton Tech Solutions
Kellton Tech Solutions share price opened at ₹ 111.35 on the BSE on Tuesday at at the time of opening was trading higher compared to previous day's closing price of ₹ 109.95. The Kellton Tech Solutions share price thereafter gained to intraday highs of 112.30, which meant gains of more than 2% on a day when Sensex was down more than 1.5% down amid stock market crash.
Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before taking any investment decisions.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
18 minutes ago
- Mint
Recommended stocks to buy today, 20 June, by India's leading market experts
On June 19, Indian stocks closed slightly lower in a choppy session, with the Nifty 50 slipping below 24,800 as most sectors—auto being the lone exception—saw selling pressure. The market opened flat-to-negative and spent the day trading in a tight band, buffeted by mixed global cues after the US Federal Reserve held rates steady but warned of higher inflation and slower growth ahead. Mounting geopolitical strains in the Middle East further dampened sentiment. By the bell, the Sensex had lost 82.79 points (0.10%) to end at 81,361.87, while the Nifty dropped 18.80 points (0.08%) to finish at 24,793.25. Broader gauges underperformed, with the BSE Midcap and Smallcap indices each sliding over 1.5%. Top 3 stocks recommended for today by Ankush Bajaj Why it's recommended: Eicher Motors recently broke out above the upper trendline of a falling wedge pattern on the daily chart, a bullish reversal formation suggesting the end of a prior downtrend. This breakout, combined with the RSI nearing 60, indicates growing bullish momentum. The stock is showing strength with a clean breakout structure, signaling potential for near-term upside. Key metrics Resistance level: ₹5,590 (short-term target) Support level: ₹5,445 (pattern invalidation level) Pattern: Falling wedge breakout on the daily chart RSI: Approaching 60 on daily chart, indicating strengthening bullish momentum Technical analysis: The breakout from the falling wedge pattern adds weight to the bullish outlook. The RSI moving toward 60 supports the idea of momentum building up for a further upside. Price action is strong post-breakout and the stock is attempting to establish a higher base. Watch for increasing volume to confirm breakout validity. Risk factors: Although the RSI is not overbought, a rapid rise could lead to brief consolidations or pullbacks. A drop below ₹5,445 would invalidate the breakout, potentially attracting sellers. Volume follow-through remains crucial for confirming strength beyond the breakout level Buy at: ₹5,493.50 Target price: ₹5,590 Stop loss: ₹5,445 Also read: Why some Indian companies are paying dividends despite posting losses Why it's recommended: Bharti Airtel is showing signs of bullish momentum with the RSI at 58 on the daily chart and trending upward, indicating improving strength in the current move. On the 45-minute timeframe, the stock is forming a triangle pattern and is poised for a breakout. If it sustains above ₹1,880, a sharp move up is anticipated. Key metrics: Resistance level: ₹1,898- ₹1,904 (short-term target) Support level: ₹1,860 (pattern invalidation level) Pattern: Triangle breakout setup on lower timeframe (45-min) RSI: Rising toward 60 on the daily chart, showing a strengthening bullish trend. Technical analysis: The convergence of a rising daily RSI and a triangle breakout setup on the lower timeframe supports a bullish outlook. Sustained movement above ₹1,880 will confirm the breakout, with potential for a quick move toward the ₹1,900+ zone. Price structure remains strong, and buyers appear to be stepping in around key support zones Risk factors: While the RSI is still below overbought levels, a breakout failure below ₹1,860 would invalidate the setup and could lead to short-term weakness or consolidation. Volume confirmation near ₹1,880 is key to validating the breakout attempt. Buy at: ₹1,877.00 Target price: ₹1,898- ₹1,904 Stop loss: ₹1,860.00 Also read | The honest taxpayer's dilemma: When rules become a disadvantage in investing Why it's recommended: M&M is exhibiting strong bullish momentum, with the RSI at 59 on the daily chart, indicating a steady upward trend. On the lower timeframe, the stock has broken out of a triangle pattern, which suggests the end of consolidation and the start of a new leg higher. If this breakout holds, further upside toward the ₹3,200+ zone is expected. Key metrics: Resistance level: ₹3,200– ₹3,225 (short-term target) Support level: ₹3,028 (pattern invalidation level) Pattern: Triangle breakout on lower timeframe RSI: At 59 on daily chart, indicating bullish momentum building. Technical analysis: The triangle breakout in lower timeframes complements the daily chart's bullish RSI structure. The stock is trading with strong price action and has potential for continuation if it maintains above the breakout level. Momentum indicators support further upside, especially if volume confirms the move Risk factors: While the RSI is rising, a pullback may occur if the price fails to hold above the breakout level. A break below ₹3,028 would invalidate the setup and may lead to short-term downside pressure. Watch for volume confirmation to support the bullish move. Buy at: ₹3,094.80 Target price: ₹3,200– ₹3,225 Stop loss: ₹3,028.00 Here are two stocks to trade today, as recommended by Trade Brains Portal Target price: ₹405 in 16-24 months Stop loss: ₹320 Why it's recommended: Founded in 1978, Biocon Ltd is the top biopharma firm in India, improving the lives of people in more than 120 countries by developing novel and cost-effective treatments for cancer, diabetes, and autoimmune diseases. The company employs more than 18,200 people who work in the research services, biosimilars, generics, and new biologics divisions. The largest integrated insulin manufacturing and research and development facility in Malaysia is operated by Biocon, which also contains one of the biggest biomanufacturing facilities for insulin, monoclonal antibodies, and devices. The group's four incubated businesses are Biocon Biologics, which focuses on biosimilars and accounts for 58% of total revenue in FY25; the generics division, which contributes 19%; and Syngene, which provides research services and accounts for 23% of total revenue in FY25. When comparing the performance on a like-for-like basis, revenue from operations totalled ₹15,262 crore, a 10% year-on-year increase; Ebitda reached ₹4,374 crore with a margin of 27%, and the net profit in FY25 was ₹1,013 crore, which represents a significant turnaround. The company has launched several new products, such as Liraglutide in the UK, Dasatinib in the US, and YesintekTM, which boosted revenue performance in Q4FY25. Going forward, the company plans to invest $200-250 million in capital expenditures across several business segments. While Syngene will increase the capacity of its research centres and production facilities for large and small compounds, BBL wants to expand its insulin factory in Malaysia as part of its capital expenditure plans. It is anticipated to spend $50 million in capital expenditures on generics in the upcoming year. The business anticipates approving generic Copaxone in the US and launching liraglutide there. According to management, Lenalidomide will be introduced in limitless quantities, with more launches scheduled for FY26. Additionally, five other products—Stelara, Bevacizumab, Aspart, Aflibercept, and Denosumab—will be introduced during the next 12 to 18 months. Risk Factor: If clearances from the US Food and Drug Administration, the European Medicines Agency, and those in the Asian and Latin American markets are delayed, their biosimilar business may miss out on opportunities. Additionally, the company faces fierce competition from a number of cost-competitive Indian enterprises as well as strong defense tactics from innovative companies that produce authorized generics. Target price: ₹1,050 in 16-24 months Stop loss: ₹730 Why it's recommended: Titagarh Rail Systems was founded in 1997 and has over 25 years of expertise as a top provider of comprehensive mobility solutions in India. Its main activities include the production of passenger coaches, propulsion equipment, urban metros, semi-high-speed trains, and a variety of wagons, including specialized ones. With four production sites, the firm can now produce 12,000 wagons and 300 coaches annually, processing about 30,000 tonnes of casting steel. As of FY25, their entire order book was worth ₹11,200 crore. Titagarh Rail Systems is the only Indian company that produces both wagons and coaches. In FY25, operational revenue was ₹3,867 crore, a slight increase over ₹3,853 crore in FY24; however, it increased 18% CAGR since FY23. PAT stood at ₹274 crore, down 4.9% from ₹288 crore in FY24; however, it has been increasing at a robust CAGR of 43% since FY23. In FY25, the FRS segment's revenue was ₹3,610.27 crore, up 5.64% year over year. In FY25, the PRS segment's income was ₹255.55 crore. The company achieved a record for the most wagons ever produced in a single year in India, with 9,431 wagons. In FY25, it produced 27,240 metric tonnes in the foundry, setting a new production record. In order to increase its production to a significantly higher level in FY26, the company plans to expand its foundry by constructing fully modern foundry production facilities. About 40,000 tonnes of castings are what the company hopes to produce in the first phase of production in FY26. Since the supply chain problems with China have been fixed, the business anticipates that manufacturing for the Bangalore Metro will be rather streamlined. It is anticipated that production will be completely simplified starting in Q2 of FY26. Starting in FY26, the company plans to increase its propulsion division by between 125 and 150 traction motors every month, or 1,500 to 1,800 traction motors per month. The company has its sights set on winning a number of projects from the enormous potential pipeline. Among the major projects are the anticipated ₹15,800 crore Metro coach contracts and the ₹72,000 crore Vande Bharat Coach. Risk Factor: More than 90% of the company's operating revenues come from freight rail systems and wagons, and Indian Railways continues to be the company's biggest source of sales. Additionally, geographically speaking, the company works on nearly all local projects and has little to no exposure to international enterprises. Two stock recommendations by MarketSmith India Why it's recommended: Capital infusion by promoters, seasonal positive tailwind, EPS growth. Key metrics: P/E: 34.54 | 52-week high: ₹1,064 | Volume: ₹354.22 crore Technical analysis: 50-DMA retake, positive institutional holding Risk factors: Increased raw-material cost and margin pressure, high operational leverage, competitive and regulatory risk. Buy at: ₹638.50 Target price: ₹740 in two to three months Stop loss: ₹687 Why it's recommended: Strong Q4 performance, expansion in mobility business, growth in consumer business. Key metrics: P/E: 47.42 | 52-week high: ₹39,088 | Volume: ₹68.04 crore Technical analysis: Trending above all key moving averages, bullish continuation pattern. Risk factors: Supply chain, currency risk, competition and regulatory pressure. Buy at: ₹32,375 Target price: ₹36,200 in two to three months Stop loss: ₹30,300 Also Read: Is the Israel-Iran war a billion-dollar threat to Adani Ports & SEZ? Two stocks to trade, recommended by NeoTrader's Raja Venkatraman BODALCHEM: Buy above: ₹68 | Stop: ₹64.50 | Target: ₹74-78 LTFOODS: Buy above: ₹426 | Stop: ₹410 | Target: ₹475-495 MarketSmith India is a stock research platform and advisory service focused on the Indian stock market. Trade name: William O'Neil India Pvt. Ltd. (Sebi Registered Research Analyst Registration No.: INH000015543). Trade Brains Portal is a stock analysis platform. Its trade name is Dailyraven Technologies Pvt. Ltd, and its Sebi-registered research analyst registration number is INH000015729. Ankush Bajaj is a Sebi-registered research analyst. His registration number is INH000010441. Raja Venkatraman is co-founder, NeoTrader. His Sebi-registered research analyst registration no. is INH000016223. Investments in securities are subject to market risks. Read all the related documents carefully before investing. Registration granted by Sebi and certification from NISM in no way guarantees performance of the intermediary or provide any assurance of returns to investors. Disclaimer: The views and recommendations given in this article are those of individual analysts. These do not represent the views of Mint. We advise investors to check with certified experts before making any investment decisions.
Mint
18 minutes ago
- Mint
HDB Financial Services IPO: Price band set at ₹700-740 per share; check GMP, issue details, more
HDB Financial Services IPO price band: The HDB Financial Services IPO price band has been fixed in the range of ₹ 700 to ₹ 740 per equity share of the face value of ₹ 10. The HDB Financial Services IPO date of subscription is scheduled for Wednesday, June 25, and will close on Friday, June 27. The allocation to anchor investors for the HDB Financial Services IPO is scheduled to take place on Tuesday, June 24. The floor price and the cap price are 70 times and 74 times the face value of the equity shares, respectively. HDB Financial Services IPO lot size is 20 equity shares and in multiples of 20 equity shares thereafter. HDB Financial Services IPO has reserved not more than 50% of the shares in the public issue for qualified institutional buyers (QIB), not less than 15% for non-institutional Institutional Investors (NII), and not less than 35% of the offer is reserved for retail investors. The employee reservation portion has been reserved equity shares aggregating up to ₹ 200 million, and HDFC Bank shareholder reservation portion consists of equity shares aggregating up to ₹ 12,500 million. Tentatively, HDB Financial Services IPO basis of allotment of shares will be finalised on Monday, June 30, and the company will initiate refunds on Tuesday, July 1, while the shares will be credited to the demat account of allottees on the same day following the refund. HDB Financial Services share price is likely to list on BSE and NSE on Wednesday, July 2. HDB Financial Services is expected to finalise the share allotment basis for its IPO on Monday, June 30. Refunds are set to be processed on Tuesday, July 1, and on the same day, shares will be credited to the demat accounts of those who were allotted shares, following the refunds. HDB Financial Services shares are anticipated to be listed on the BSE and NSE on Wednesday, July 2. The IPO consists of a fresh issue of ₹ 2,500 crore along with an offer for sale of ₹ 10,000 crore from HDFC Bank. The net proceeds are intended to be used to enhance the company's Tier-I Capital base, allowing them to fulfill future capital needs for their various business segments, including Enterprise Lending, Asset Finance, and Consumer Finance. These needs are anticipated to emerge from the growth of the company's operations and assets, and to maintain adherence to the capital adequacy regulations established by the RBI as they may evolve. JM Financial Limited, BNP Paribas, Bofa Securities India Limited, Goldman Sachs (India) Securities Private Limited, HSBC Securities & Capital Markets Pvt Ltd, IIFL Capital Services Limited, Jefferies India Private Limited, Morgan Stanley India Company Pvt Ltd, Motilal Oswal Investment Advisors Limited, Nomura Financial Advisory And Securities (India) Pvt Ltd, Nuvama Wealth Management Limited, and UBS Securities India Private Limited serve as the book running lead managers for the HDB Financial IPO, while MUFG Intime India Private Limited (Link Intime) acts as the registrar for the offering. HDB Financial Services ranks as the seventh largest, diversified retail-focused non-banking financial company (NBFC) in India, with a total gross loan book amounting to ₹ 902.2 billion as of March 31, 2024, among its NBFC competitors, according to the CRISIL Report. According to the red herring prospectus (RHP), the company's competitors include Bajaj Finance Ltd (with a P/E of 34.3), Sundaram Finance Ltd (with a P/E of 28.1), L&T Finance Ltd (with a P/E of 17.9), Mahindra & Mahindra Financial Services Ltd (with a P/E of 14.5), Cholamandalam Investment and Finance Company Ltd (with a P/E of 31.4), and Shriram Finance Ltd (with a P/E of 13.0). The Reserve Bank of India (RBI) classifies the company as an Upper Layer Non-Banking Financial Company (NBFC-UL). The NBFC provides a diverse range of lending products designed to meet the needs of a growing customer base through an extensive omni-channel distribution network. HDFC Bank holds a 94.3% stake in HDB Financial prior to the IPO. As of March 31, 2025, HDB Financial Services reported total gross loans of ₹ 1,068.8 billion, representing a compound annual growth rate (CAGR) of 23.54% from March 31, 2023, to March 31, 2025. Their assets under management reached ₹ 1,072.6 billion as of March 31, 2025, reflecting a CAGR of 23.71% from Fiscal 2023 to Fiscal 2025. In fiscal 2025, the NBFC achieved a profit after tax of ₹ 21.8 billion, indicating a CAGR of 5.38% between Fiscal 2023 and Fiscal 2025. Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
Time of India
20 minutes ago
- Time of India
Insurtech firm Renewbuy bags $10 million from Apis, 360 One
Insurance broking startup Renewbuy has secured $10 million (about Rs 86 crore) in a funding round from existing investors, London-based Apis Partners and 360 One (previously IIFL Wealth), according to people with knowledge of the matter. It comes at a time when the Gurgaon-based insurance startup is in the process of merging with rival insurance broker InsuranceDekho. 'These funds will help in business development till the time the merger gets closed,' said one of the persons, who did not wish to be identified. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Jämför elpriser (Billigast) Undo Renewbuy did not respond to queries from ET. ET had reported on October 28, 2024, that InsuranceDekho was looking to acquire Renewbuy, valuing the startup at around $300-350 million, thereby creating a billion dollar merged entity in the insurance broking segment. Live Events While the deal is in the works, it is yet to be approved by the Insurance Regulatory and Development Authority of India. Discover the stories of your interest Blockchain 5 Stories Cyber-safety 7 Stories Fintech 9 Stories E-comm 9 Stories ML 8 Stories Edtech 6 Stories The company plans to use the funds to run the business and expand its operations in the interim period. Renewbuy, founded in 2014, has raised $141 million since inception from large investors such as Japanese insurance firm Dai-ichi Life Insurance, Apis Partners and Lok Capital. After the last equity funding in June 2023, the startup was valued at around $324 million, according to Tracxn. Renewbuy sells motor health and life insurance products through a network of physical agents — or point of sales persons, in industry parlance. For 2023-24, the company reported total revenue of Rs 410 crore and net loss of Rs 114 crore. The startup competes with three other major players in this segment — CarDekho-backed InsuranceDekho, Peak XV Partners-backed Turtlemint and PB Partners, a subsidiary of Policybazaar.
